Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

ized and 219 patients were treated with balanced distribution over five groups.  The control group received macular laser therapy at baseline, and patients were eligible for repeat laser treatments, but no more frequently than at 16 week intervals.  Two groups received monthly doses of 0.5 or 2mg of VEGF Trap-Eye throughout the 12-month dosing period.  Two groups received three initial monthly doses of 2mg of VEGF Trap-Eye (at baseline and weeks 4 and 8), followed through week 52 by either every two months dosing or PRN (as-needed) dosing with very strict repeat dosing criteria. Mean gains in visual acuity versus baseline were as follows:Laser

0.5mg

monthly

2mg

monthly

2mg

every two

months*

2mg

PRN*n

44

44

44

42

45Mean change in visual acuity at week 24 versus baseline(1) (letters)

2.5

8.6**

11.4**

8.5**

10.3**Mean change in visual acuity at week 52 versus baseline (letters)

-1.3

11.0**

13.1**

9.7**

12.0***Following 3 initial monthly doses

**p<0.01 versus laser

(1) Primary endpointNo significant differences among the VEGF Trap-Eye arms were observed.  Approximately 80 percent of the VEGF Trap-Eye patients and 75 percent of the laser patients remained in the study through 52 weeks.

VEGF Trap-Eye was generally well-tolerated, and there were no ocular or non-ocular drug-related serious adverse events reported in the study.  The most common adverse events reported were those typically associated with intravitreal injections or the underlying disease. The most frequent ocular adverse events reported among patients receiving VEGF Trap-Eye included conjunctival hemorrhage, eye pain, ocular redness (hyperemia), and increased intraocular pressure.  The incidence of non-ocular serious adverse events was generally well balanced between all treatment arms. 
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015   AMC Health , ... showcase advances in monitored care that are transforming chronic ... ATA 2015 Conference, May 2-5 at the ... Health will share information about how their innovative ... help transform and personalize healthcare delivery at Booth #2116 ...
(Date:4/27/2015)... NEW YORK , April 27, 2015 ... claims against the board of directors of Aerie Pharmaceuticals, ... concerning whether the board has breached its fiduciary duties ... Company issued a press release announcing results from its ... things, the press release disclosed that in the trial, ...
(Date:4/27/2015)... 2015  USL di Reggio Emilia, the Regional Health ... has implemented Zebra Technologies Corporation (NASDAQ: ... Wireless Network Solution (WNS) provided by Zebra has ... in real time via mobile computers, contributing to improved ... also provides employee and guest Wi-Fi access and enables ...
Breaking Medicine Technology:AMC Health to Showcase Advances in Monitored Care at ATA 2015 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 4Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 4Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 5
... NEW YORK, Nov. 9 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. ... pharmaceutical,company dedicated to improving health through the development, manufacture ... the counter ("OTC"),products, today announced that it plans to ... 2009, after the market closes. , ...
... 9, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today ... , Arena reported a lower net loss allocable to common stockholders ... per share, compared to a net loss allocable to common stockholders ... per share, and a net loss allocable to common stockholders in ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9
(Date:4/27/2015)... 2015 According to a recent report ... after chronic back pain, TMJ disorders are the ... and disability. In addition, the report revealed that TMJ ... population, costing an estimated 4 billion dollars annually. , ... from seemingly unrelated symptoms such as headaches, neck pain, ...
(Date:4/27/2015)... 2015 The Doctors on Liens ... of personal injury attorneys with the best doctors working on ... steady growth throughout their history and that trend continues with ... and his team in the Tujunga / Sunland ... massage therapist, patients can find comprehensive care and detailed documentation ...
(Date:4/27/2015)... NJ (PRWEB) April 27, 2015 ... firm, is proud to announce their sponsorship of ... Warren Counties. Girls on the Run is ... third through eighth grade. The program is delivered ... with uplifting workouts aimed to develop the whole ...
(Date:4/27/2015)... April 27, 2015 Ticket Down is ... at the Alpine Valley Music Theatre and the Isleta ... and Albuquerque, New Mexico area can celebrate because their ... the woods. Buffett will be performing alongside legendary ... His tour stops during the summer and fall months ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 The Mount ... a seamless referral process for the Health System’s care ... heart failure or diabetes, for instance, may have more ... physicians coordinate with many other care providers. With medical ... of thousands of patients each year, the need for ...
Breaking Medicine News(10 mins):Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:TayganPoint Consulting Group Announces Sponsorship of Girls on the Run 2Health News:Cheap Jimmy Buffett Tickets at Alpine Valley Music Theatre in Elkhorn, WI and at Isleta Amphitheater in Albuquerque, NM Now on Sale at TicketDown.com 2Health News:Mount Sinai Launches System for Faster Referrals 2Health News:Mount Sinai Launches System for Faster Referrals 3
... ... contacted the Metropolitan Washington, DC Chapter of the Cystic Fibrosis (CF) Foundation 12 ... Melissa and 3-year old son Matthew had recently been diagnosed with the genetic ... age of survival for a child with CF was about 20 years. ...
... ... falling apart at home, psychotherapeutic interventions provide families with a growing array of options. ... (PRWEB) February 25, 2010 -- ... apart at home, psychotherapeutic interventions provide families with a growing array of options., , ,There ...
... ... braking system, affects millions of drivers , ... New York, NY (Lexis Nexis) February 25, 2010 -- The ... led to a significant increase in inquiries from individuals who are concerned about the ...
... A new study found that fluoxetine (Prozac) and ... collagen-induced arthritis (CIA) in mice. Research led ... Sussex Medical School (BSMS) in the UK studied ... selective serotonin reuptake inhibitors (SSRIs), most commonly used ...
... Special Issue of Business Horizons ( www.elsevier.com/locate/bushor ... Indiana University, and published by Elsevier, addresses issues central ... has been at the center of U.S. political debate ... support from Congress for passage of a national system ...
... ... ... ... ...
Cached Medicine News:Health News:Cystic Fibrosis Foundation Awards CGI Corporation of the Year 2Health News:Cystic Fibrosis Foundation Awards CGI Corporation of the Year 3Health News:New Approaches to Teen Therapy Bring Results 2Health News:New Approaches to Teen Therapy Bring Results 3Health News:New Approaches to Teen Therapy Bring Results 4Health News:New Approaches to Teen Therapy Bring Results 5Health News:Toyota Recalls Raise Awareness of Vehicle Safety Issues, Risks of Accidents from Driving Defective Automobiles 2Health News:Prozac and Celexa exhibit anti-inflammatory effects 2Health News:New Business Horizons special issue on US health care 2Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 2Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 3Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 4Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 5Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 6Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 7
... offers a range of standard, enhanced ... delivers therapy to meet the needs ... in commercial and clinical effectiveness and ... the SleepStyle 200 series is the ...
... The ResMed S6 Lightweight II CPAP ... microprocessor-controlled motor that maintains consistent pressure. ... and adjusting the settings easy, and ... and make adjustments is simple. This ...
The S8 Escape is the economy model of ResMeds S8 series. The S8 Escape is ideal for patients who want the convenience and portability of the S8 models but do not require the added comfort features of...
The S7 Elite is the premium device in ResMeds award-winning S7 series. All S7 devices include an option of integrated humidification....
Medicine Products: